Welcome to our dedicated page for Bausch + Lomb Corporation SEC filings (Ticker: BLCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bausch + Lomb Corporation filings document the reporting obligations of a Canada-incorporated eye health company whose common shares trade on the New York Stock Exchange and Toronto Stock Exchange under BLCO. Its 8-K reports cover quarterly and annual operating results, non-GAAP financial measures, guidance, investor presentations, material credit-agreement amendments and refinancing activity.
Proxy materials describe annual shareholder meeting matters, board composition, director independence, committee assignments and executive compensation governance. Other event filings record board appointments, committee changes, registered common-share details and Regulation FD disclosures tied to the company's product pipeline, Pharmaceuticals, Surgical and Vision Care operations.
Bausch & Lomb Corp director Alfonso Eduardo increased his stake through an open-market purchase and a related equity award. He bought 4,300 common shares at a price of $17.90 per share, bringing his directly held shares to 9,555 immediately after the purchase.
In connection with this purchase and under the company’s matching share program, he was granted 4,300 matching restricted share units, which raised his total direct holdings to 13,855 common shares. One-third of these matching restricted share units will vest on each of the first, second, and third anniversaries of the grant date, subject to his continued service, apart from limited circumstances.
Bausch & Lomb Corp director Andrew C. Von Eschenbach reported two transactions in common shares. He made an open-market purchase of 4,364 shares at $18.305 per share, increasing his direct holdings to 66,450 shares. In connection with this purchase, he also received a grant of 4,364 matching restricted share units under the company’s matching share program, which will vest in three equal installments on each of the first, second, and third anniversaries of the grant date, subject to his continued service.
Bausch & Lomb Corp senior vice president, controller and chief accounting officer Frederick Munsch reported multiple share dispositions related to tax withholding. On February 27, he disposed of 2,437 and 5,692 common shares at $18.30 per share through tax-withholding transactions. On February 26, he disposed of an additional 2,042 common shares at $18.49 per share, also for tax withholding.
According to the footnotes, these shares were withheld to cover tax obligations due upon the vesting of restricted share units and performance-based restricted share units, rather than being discretionary open-market sales.
Bausch & Lomb Corp executive Andrew J. Stewart reported tax-related share dispositions tied to vesting of restricted share units. On February 26, he had 2,984 common shares withheld at $18.49 per share to cover tax obligations, leaving 92,656 common shares owned directly afterward.
On February 27, an additional 2,007 common shares were withheld at $18.30 per share for the same purpose, leaving him with 90,649 directly owned common shares following this transaction. These Form 4 entries reflect tax-withholding dispositions rather than open-market purchases or sales.
Bausch & Lomb Corp executive Luc Bonnefoy, President of Surgical, reported tax-related dispositions of common shares tied to equity awards. On February 26, 2026, 4,404 common shares at $18.49 per share were withheld to cover tax obligations upon vesting of restricted share units, leaving 113,533 shares held directly.
On February 27, 2026, 4,311 common shares and 9,221 common shares, each at $18.30 per share, were similarly withheld to satisfy tax liabilities on vesting of restricted and performance-based restricted share units, leaving 109,222 and 100,001 common shares, respectively, held directly after these transactions.
Bausch & Lomb Corp executive Yehia Hashad reported tax-related share dispositions. On February 26–27, he had several Form 4 transactions coded "F," where common shares were withheld at prices around $18.30–$18.49 to cover tax obligations upon vesting of restricted and performance-based restricted share units. After one February 27 transaction, he held 180,041 common shares directly.
Bausch & Lomb Corp executive Robert D. Bailey reported routine share dispositions related to tax withholding on vested equity awards. On two dates, he surrendered 3,395 and 2,461 common shares, respectively, at prices of $18.49 and $18.30 per share to cover tax obligations on restricted share unit vesting, rather than selling shares on the open market. After these tax-withholding transactions, he directly holds 217,290 common shares.
Bausch & Lomb EVP and CFO Sam Eldessouky reported tax-withholding dispositions of common shares related to equity awards. On February 26–27, 2026, he delivered 15,507, 51,470 and 7,062 common shares at prices of $18.30 and $18.49 per share to satisfy tax obligations.
Footnotes explain these shares were withheld upon vesting of restricted share units and performance-based restricted share units, rather than sold in open-market transactions. Eldessouky retains a significant direct holding of Bausch & Lomb common shares after these tax-withholding events.
Bausch & Lomb Corp CEO and Chairman Brent L. Saunders reported two Form 4 transactions reflecting common shares withheld to cover taxes on restricted share units that vested. On February 26, 22,059 common shares at $18.49 per share were withheld. On February 27, an additional 24,649 common shares at $18.30 per share were withheld. These are coded as tax-withholding dispositions rather than open-market sales, and Saunders held 951,875 common shares directly after the most recent transaction.
Munsch Frederick reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corporation Senior Vice President, Controller and Chief Accounting Officer Frederick Munsch received an equity award of 18,253 common shares in the form of restricted share units. The grant was made at no cash cost to him as part of the company’s 2022 Omnibus Incentive Plan.
The RSUs are scheduled to vest in three equal installments on each of the first three anniversaries of the grant date, subject to his continued service and the plan and award agreement terms. After this award, he beneficially owns 108,484 common shares directly.